Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 10/20 | 0.45 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.44 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2728930 | 0.90 | L3MBTL1 (0.44) | CD274L3MBTL1MEN1KMT2AKDM4E | |
| SCHEMBL15084388 | 0.88 | CD274 (0.45) | CD274SLC6A1PDCD1L3MBTL1MEN1 | |
| SCHEMBL15084376 | 0.78 | L3MBTL1 (0.44) | CD274L3MBTL1MEN1KMT2AKDM4E | |
| Trifluoroacetic Acid SCHEMBL14893164 | 0.78 | SLC6A1 (0.55) | CD274SLC6A1L3MBTL1MEN1KMT2A | |
| SCHEMBL21338426 | 0.76 | DRD4 (0.51) | L3MBTL1MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL15081968 | 0.76 | TACR1 (0.42) | CD274L3MBTL1MEN1KMT2AKDM4E | |
| SCHEMBL15084392 | 0.76 | S1PR1 (0.46) | L3MBTL1MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL15084321 | 0.76 | MAPK1 (0.51) | MAPK1SMN1; SMN2 | |
| SCHEMBL807590 | 0.75 | L3MBTL1 (0.42) | CD274L3MBTL1MEN1KMT2AKDM4E | |
| SCHEMBL10212863 | 0.74 | S1PR5 (0.47) | L3MBTL1KDM4EALDH1A1TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3536319-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-09-11 | — | — | EP | disclosed |
| EP-3536319-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-09-11 | — | — | EP | disclosed |
| US-8999966-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-04-07 | — | — | US | disclosed |
| US-8999966-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-04-07 | — | — | US | disclosed |
| US-8999966-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20130237518-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP | 2013-09-12 | — | — | US | disclosed |
| US-20130237518-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP | 2013-09-12 | — | — | US | disclosed |
| US-20130237518-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP | 2013-09-12 | — | — | US | disclosed |
| EP-2632268-A2 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-09-04 | — | — | EP | disclosed |
| WO-2012058127-A2 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | SCHERING CORPORATION (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237518-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAPK4, MAP3K20 | CD274 3013/4885SLC6A1 4503/4885PDCD1 1401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.